Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares of the company's stock for approximately $1.74 million, resulting in a 96.85% decrease in her ownership.
• Shares of United Therapeutics have recently traded down by 3%, closing at $425.42, with a 1-year trading range between $266.98 and $442.01.
• Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price averaging $438.85, reflecting bullish sentiment following upward revisions from several investment firms.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $434.12, for a total transaction of $1,736,480.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company's stock, valued at approximately $56,435.60. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Trading Down 3.0%

Shares of NASDAQ:UTHR traded down $13.33 on Thursday, hitting $425.42. 966,491 shares of the company were exchanged, compared to its average volume of 584,076. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $442.01. The stock's 50 day moving average price is $337.52 and its 200 day moving average price is $313.10. The firm has a market capitalization of $19.19 billion, a P/E ratio of 16.61, a price-to-earnings-growth ratio of 6.62 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 earnings per share. The company's quarterly revenue was up 11.7% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. F m Investments LLC increased its holdings in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after buying an additional 33 shares in the last quarter. HB Wealth Management LLC increased its holdings in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock valued at $355,000 after buying an additional 35 shares in the last quarter. Hohimer Wealth Management LLC increased its holdings in United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after buying an additional 37 shares in the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares in the last quarter. Finally, Park Avenue Securities LLC increased its holdings in United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock valued at $676,000 after buying an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 10th. Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. Oppenheimer boosted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.